scholarly journals Messages for patients and relatives from the 2021 update of the guideline on acute therapy and management of anaphylaxis

2021 ◽  
Author(s):  
Johannes Ring ◽  
Kirsten Beyer ◽  
Tilo Biedermann ◽  
Andreas Bircher ◽  
Matthias Fischer ◽  
...  
Keyword(s):  
Acute Therapy

Thrombolytic Treatment of Acute Cerebral Infarction

CNS Spectrums ◽  
2005 ◽  
Vol 10 (7) ◽  
pp. 539-549 ◽  
Author(s):  
Kathleen M. Burger ◽  
Deborah R. Horowitz
Keyword(s):  
Case Reports ◽  
Optimal Management ◽  
Thrombolytic Treatment ◽  
Acute Stroke Patient ◽  
Acute Therapy ◽  
Common Cause ◽  
Intravenous Tissue Plasminogen Activator ◽  
The World ◽  
Tissue Plasminogen ◽  
Improved Outcome

AbstractStroke is a common cause of death and disability throughout the world. Acute neurologic deficits due to ischemic injury deserve rapid recognition and diagnosis in order to provide effective therapy. Intravenous tissue plasminogen activator (t-PA) provided to carefully selected patients that can be treated within 3 hours of stroke onset results in improved outcome in these patients. Intra-arterial administration of t-PA within a 6-hour window is performed at several academic centers in patients with middle cerebral and other intracranial artery occlusions based on results of one randomized clinical trial and numerous case reports. Although acute therapy of ischemic stroke has received much attention since the approval of intravenous t-PA, only a small percentage of individuals suffering a stroke actually receive t-PA. This article will review the optimal management of the acute stroke patient and discuss thrombolytic clinical trials that have been completed as well as those that are in progress.

scholarly journals Analysis of a Coordinated Stroke Center and Regional Stroke Network on Access to Acute Therapy and Clinical Outcomes

Stroke ◽  
2013 ◽  
Vol 44 (1) ◽  
pp. 132-137 ◽  
Author(s):  
Marilyn M. Rymer ◽  
Edward P. Armstrong ◽  
Gary Walker ◽  
Sissi Pham ◽  
Denise Kruzikas
Keyword(s):  
Clinical Outcomes ◽  
Acute Therapy ◽  
Stroke Center

scholarly journals Randomized Trial of Trimethoprim-Sulfamethoxazole versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients with AIDS

1998 ◽  
Vol 42 (6) ◽  
pp. 1346-1349 ◽  
Author(s):  
Donato Torre ◽  
Salvatore Casari ◽  
Filippo Speranza ◽  
Alessandra Donisi ◽  
Giampietro Gregis ◽  
...  
Keyword(s):  
Bacterial Infections ◽  
Adverse Reactions ◽  
Common Adverse Event ◽  
Toxoplasmic Encephalitis ◽  
Efficacy And Safety ◽  
Acute Therapy ◽  
Valuable Alternative ◽  
Significant Difference ◽  
To Receive ◽  
Present Pilot Study

ABSTRACT The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS. This was a pilot, multicenter, randomized, and prospective study. Patients were randomly assigned to receive TMP (10 mg/kg of body weight/day) and SMX (50 mg/kg/day) or P (50 mg daily) and S (60 mg/kg/day) as acute therapy (for 4 weeks) and then as maintenance therapy for 3 months at half of the original dosage. Seventy-seven patients were enrolled and randomized to the study: 40 patients were treated with TMP-SMX and 37 were treated with P-S. There was no statistically significant difference in clinical efficacy during acute therapy. In contrast, patients randomized to TMP-SMX appeared more likely to achieve a complete radiologic response after acute therapy. Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients. In conclusion, the results of the study suggest that TMP-SMX appears to be a valuable alternative to P-S, in particular in patients with opportunistic bacterial infections.

Abstract 2399: Low Hospital Mortality Of Acute Myocardial Infarction In Cslinical Practice Due To Optimized Guideline Oriented Treatment: Results Of The Optami-registry

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Anselm K Gitt ◽  
Harm Wienbergen ◽  
Uwe Zeymer ◽  
Frank Towae ◽  
Martin G Gottwik ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Practice ◽  
Hospital Mortality ◽  
Randomized Trials ◽  
Patient Characteristics ◽  
High Rate ◽  
Internal Quality ◽  
Acute Therapy ◽  
Early Invasive Strategy

Background: Hospital mortality of STEMI in recent randomized trials as ASSENT IV ranges between 3.5 and 6.0%. Although registry data have shown a constant improvement of myocardial infarction outcome over the past years due to better implementation of guidelines for the management of acute myocardial infarction, hospital mortality in clinical practice still was much higher than in the selected patient population of randomized trials. Can ongoing registries in clinical practice as quality assurance programmes further reduce hospital mortality of acute myocardial infarction? Methods: The OPTAMI Register (Optimized Therapy of Acute Myocardial Infarction) enrols consecutive patients with STEMI or NSTEMI in 33 Centres (27 with cathlab facilities) in Germany to document patient characteristics, acute therapy as well as hospital outcome. All centres are provided benchmark reports for internal quality control. Results: Out of 1139 enrolled patients, 629 (55%) presented with STEMI and 510 (45%) with NSTEMI. Patients with NSTEMI were older, more often female and had a significantly higher prevalence of relevant comorbidities. OPTAMI documented an extraordinary high rate of primary PCI in STEMI as well as a high rate of early invasive strategy with PCI <48h in NSTEMI. In both groups, adherence to guidelines for the acute adjunctive medical treatment including antiplatelet therapy, betablockers, ACE-inhibitors and statins was higher than ever documented in any German MI registry. Hospital mortality was 4.0% in consecutive patients with STEMI and 3.9% in consecutive patients with NSTEMI. Conclusion: Preliminary data of the ongoing OPTAMI Registry demonstrate that in selected cnetres (mainly with cath lab facilities) hospital mortality in clinical practice can be reduced to levels of randomised controlled trials by adherence to practice guidelines for the management of acute myocardial infarctions.

Abstract 2097: Acute Ventricular Unloading in Dogs with Chronic Heart Failure: Comparison Between Intra-Aortic Balloon Counterpulsation and Continuous Aortic Flow Augmentation

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Mengjun Wang ◽  
Robert Brewer ◽  
Itamar Ilsar ◽  
Alice Jiang ◽  
Tony Viole ◽  
...  
Keyword(s):  
Heart Failure ◽  
Diastolic Pressure ◽  
Decompensated Heart Failure ◽  
Aortic Flow ◽  
Acute Therapy ◽  
Systolic Volume ◽  
End Diastolic Volume ◽  
End Systolic Volume ◽  
Intra Aortic Balloon Counterpulsation ◽  
Balloon Counterpulsation

Background: Continuous aortic flow augmentation (CAFA) therapy provided by the Cancion ® system (Orqis Medical, Inc.) for decompensated heart failure (HF)has been shown to effectively unload the left ventricle (LV) in dogs with chronic HF. In the present study, we compared the extent of acute LV unloading elicited by CAFA to that elicited by intra-aortic balloon counterpulsation (IABP) in normotensive dogs with HF produced by multiple sequential intracoronary microembolizations. Methods: Studies were performed in 6 dogs with HF. Each dog was studied with CAFA and with IABP. Studies were performed one week apart. For each study, therapy with CAFA or IABP was maintained for 4 hours. The Cancion system was positioned using a dual femoral approach configuration with constant pump flow of 250 ml/min thus superimposing an element of continuous flow on existing pulsatile aortic flow. In all dogs and with both devices, LV end-diastolic pressure (LVEDP), LV end-diastolic volume (EDV), LV end-systolic volume (ESV) and LV ejection fraction (EF) were measured at baseline prior to initiating therapy and were repeated at 2 hours and 4 hours after insituting CAFA or IABP. Results: Data (mean SEM) are shown in the table . Up to 4 hours of IABP had no significant effects on LVEDP, EDV, ESV or EF. In contrast, institution of CAFA for 4 hours significantly decreased LVEDP, EDV and ESV and significantly increased EF. Conclusions: In normotensive dogs with chronic HF and no epicardial coronary artery disease, acute therapy with IABP for up to 4 hours had no effect on LV unloading defined as a reduction in LV filling pressure and LV size. In the same cohort of dogs, CAFA therapy elicited marked LV unloading. These data indicate that CAFA is superior to IABP in achieving acute LV unloading in the setting of chronic HF not complicated by ongoing myocardial ischemia and/or cardiogenic shock.

Advances in the acute therapy of hypertension

1992 ◽  
Vol 20 (12) ◽  
pp. 1630 ◽  
Author(s):  
Michael G. Ziegler
Keyword(s):  
Acute Therapy ◽  
Therapy Of Hypertension
Sign in / Sign up

Export Citation Format

Share Document